Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Benzodiazepines: Risks and Benefits. A Reconsideration
David S Baldwin; Katherine Aitchison; Alan Bateson; H Valerie Curran; Simon Davies; Brian Leonard; David J Nutt; David N Stephens; Sue Wilson
FOCUS 2014;12:229-234. doi:10.1176/appi.focus.12.2.229

Over the last decade there have been further developments in our knowledge of the risks and benefits of benzodiazepines, and of the risks and benefits of alternatives to benzodiazepines. Representatives drawn from the Psychopharmacology Special Interest Group of the Royal College of Psychiatrists and the British Association for Psychopharmacology together examined these developments, and have provided this joint statement with recommendations for clinical practice. The working group was mindful of widespread concerns about benzodiazepines and related anxiolytic and hypnotic drugs. The group believes that whenever benzodiazepines are prescribed, the potential for dependence or other harmful effects must be considered. However, the group also believes that the risks of dependence associated with long-term use should be balanced against the benefits that in many cases follow from the short or intermittent use of benzodiazepines and the risk of the underlying conditions for which treatment is being provided.

(Reprinted with permission from the Journal of Psychopharmacology 2013; 27(11): 967–971) 

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).



Baldwin  DS;  Anderson  IM;  Nutt  DJ  et al. (2005)  Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.  J Psychopharmacol 19: 567–596.
[CrossRef] | [PubMed]
Chick  J;  Nutt  DJ (2011)  Substitution therapy for alcoholism: Time for a reappraisal? J Psychopharmacol 26: 205–212.
[CrossRef] | [PubMed]
Dell’osso  B;  Lader  M (2013)  Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry 28: 7–20.
Lingford-Hughes  A;  Welch  S;  Peters  L  et al. (2012)  BAP updated guidelines: Evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: Recommendations from BAP.  J Psychopharmacol 26: 899–952.
[CrossRef] | [PubMed]
Nutt  DJ;  Sharpe  M (2008)  Uncritical positive regard? Issues in the efficacy and safety of psychotherapy.  J Psychopharmacol 22: 3–6.
[CrossRef] | [PubMed]
Stephens  DN;  King  SL (2013)  Neuropharmacology of Benzodiazepines. In: Blume  AW;  Kavanagh  DJ;  Kampman  KM  et al. (eds)  Biological Research on Addiction: Comprehensive Addictive Behaviors and Disorders .  San Diego, USA:  Academic Press, pp.605–614.
Wilson  SJ;  Nutt  DJ;  Alford  C  et al. (2010)  British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders.  J Psychopharmacol 24: 1577–1600.
[CrossRef] | [PubMed]
References Container

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 2.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 6.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 6.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 6.  >
Topic Collections
Psychiatric News
PubMed Articles